Knobelman Deborah's most recent trade in Kronos Bio Inc was a trade of 246,390 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kronos Bio Inc | Deborah Knobelman | President & Interim CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 246,390 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Kronos Bio Inc | Deborah Knobelman | President & Interim CEO | 20 Jun 2025 | 139,422 | 0 | - | 0.6 | 79,471 | Common Stock | |
| Kronos Bio Inc | Deborah Knobelman | President & Interim CEO | Sale of securities on an exchange or to another person at price $ 0.87 per share. | 05 Jun 2025 | 24,838 | 139,422 | - | 0.9 | 21,554 | Common Stock |
| Kronos Bio Inc | Deborah Knobelman | Chief Financial Officer | 03 Jun 2024 | 246,390 | 246,390 | - | - | Employee Stock Option (Right to Buy) | ||
| Kronos Bio Inc | Deborah Knobelman | Chief Financial Officer | 03 Jun 2024 | 164,260 | 164,260 | - | 0 | Common Stock | ||
| Senti Biosciences Inc. | Knobelman Deborah | Chief Financial Officer, Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 152,000 | 152,000 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Deborah Knobelman | Chief Financial Officer, Head of Corporate Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 101,000 | 131,000 | - | 0 | Common Stock | |
| Senti Biosciences Inc. | Deborah Knobelman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Deborah Knobelman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Senti Biosciences Inc. | Deborah Knobelman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 30,000 | 30,000 | - | 0 | Common Stock |